- Home
- CAG vs MIRM Comparison
CAG vs MIRM Comparison
Compare CAG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAG | MIRM |
|---|---|---|
| Founded | 1919 | 2018 |
| Country | United States | United States |
| Employees | 26100 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 7.2B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CAG | MIRM |
|---|---|---|
| Price | $14.73 | $93.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 16 | 12 |
| Target Price | $13.74 | ★ $154.00 |
| AVG Volume (30 Days) | ★ 10.0M | 571.5K |
| Earning Date | 12-18-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $1,500,000,000.00 | $19,138,000.00 |
| Revenue This Year | N/A | $37.65 |
| Revenue Next Year | N/A | $21.04 |
| P/E Ratio | $40.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.53 | $63.23 |
| 52 Week High | $20.32 | $130.00 |
Technical Indicators
Market Signals| Indicator | CAG | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 51.12 | 59.57 |
| Support Level | $14.44 | $87.38 |
| Resistance Level | $15.44 | $98.34 |
| Average True Range (ATR) | 0.41 | 4.28 |
| MACD | 0.00 | 0.96 |
| Stochastic Oscillator | 52.87 | 68.65 |
Price Performance
Historical ComparisonAbout CAG ConAgra Brands Inc.
Conagra Brands Inc is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). The majority of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, and Wish-Bone. The company sells through the USA retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.